Simoa® assays can detect neurological biomarkers, such as Neurofilament Light (NfL), GFAP and several others associated with brain injury and disease. With Simoa®, these informative markers can be detected at much earlier stages, in serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Download our flyer to learn more about the application of bead technology for multiple sclerosis research and view a sampling of recent publications.